INTRODUCTION
Proteolysis of human fibrinogen by thrombin, plasmin [1] , neutrophil lysates [2, 3] , purified human neutrophil elastase (HNE) [4] and cathepsin G [5] yield distinct products. Thrombin and 17 and positions 14 and 15 from their N-termini respectively [6] , resulting in a series of reactions which yield fibrin. Plasmin yields an intermediate fragment X and terminal fragments D and E ( Figure 1 ) [7] . Fragments D and E both exhibit anticoagulant activity; D inhibits fibrin polymerization by binding to sites complementary to it on the E domain of the fibrin monomer, while E acts as a competitive inhibitor of the action of thrombin upon fibrinogen [8, 9] . Neutrophil fibrinogenolysis is characterized by N-terminal cleavage of all three constituent fibrinogen chains to yield fibrinopeptide A-and fibrinopeptide B-containing peptides and products having the antigenic characteristics of plasmin-derived fragments D and E, which demonstrate anticoagulant properties [3, 5, 10] . In addition, neutrophil-generated fragments that are larger than the plasmin-generated fragment X ( Figure 1 ) are found to be unclottable by thrombin [10] . A characteristic of fibrinogen degradation of neutrophil lysates [2] and HNE [4, 11, 12] is the generation of an Aal-21 peptide obtained by cleavage of the bond between the amino acids valine and glutamic acid at positions 21 and 22 respectively from the N-terminus of the Aa chain. Plasma levels of this peptide have been used as markers of HNE activity in vivo and are proposed to be useful for monitoring HNE activity in conditions where alantitrypsin inhibitor activity is compromised, and in subjects with homozygous and heterozygous deficiency of this enzyme inhibitor [4, 13] .
Recently, a high-molecular-mass (600 kDa) neutral protease associated with the neutrophil membrane, capable of degrading Aal-21 peptide, digestion of the BP chain at positions within the C-terminus, and proteolysis of the bond between amino acids isoleucine and glycine at positions 394 and 395 respectively from the N-terminus of the y chain. This generates products that lack anticoagulant activity. The thrombin clotting time of the product with an apparent molecular mass of 330 kDa was prolonged, although clot formation was still observed. Loss of coagulability and inability to clot was found with further degradation of fibrinogen to an apparent molecular mass of 290 kDa. Activity of this neutrophil membrane protease in vivo could be important for the regulation of fibrin deposition at sites of inflammation, and may contribute to the reported plasma levels of the Aal-21 peptide.
the acute-phase-reactant C-reactive protein to bioactive peptides, has been reported [14, 15] . Up-regulation of the activity and partial release of this protease into the extracellular medium was achieved by stimulating neutrophils with a concentration of phorbol 12-myristate 13-acetate (PMA) that does not induce azurophil granule release [14, 15] . The association of this protease with both neutrophil membrane and cytoskeleton fractions led to the suggestion that the enzyme is a submembrane protein localized at the site of attachment of the membrane to the cytoskeleton [15] . When these neutrophil fractions were subjected to SDS/PAGE the proteolytic activity in each fraction, responsible for degrading C-reactive protein, migrated as four discrete bands to positions corresponding to apparent molecular mass values of 200 kDa, 316 kDa, 398 kDa and 501 kDa [15] .
The present study characterizes fibrinogenolysis by this neutrophil membrane-associated protease and evaluates the capacity of this protease to act as an alternative pathway to fibrinogenolysis by plasmin and neutrophil lysosomal enzymes.
MATERIALS AND METHODS Materials
All chemicals and reagents were obtained from the Sigma Chemical Co. (St. Louis, MO, U.S.A) unless indicated otherwise.
Preparation and lodination of fibrinogen
Fibrinogen was isolated by (NH4)2S04 precipitation of plasma obtained from heparinized blood donated by healthy laboratory workers [16] . This preparation contained a trace amount of Factor XIII which was used to catalyse cross-linking during fibrin formation. The clottability of the purified fibrinogen was 97 %. Fibrinogen was iodinated using lodogen (Pierce and Figure 1 Schematic form of flbrinogen Human fibrinogen (340 kDa) is composed of two identical half molecules assembled into a dimeric structure such that each half molecule contains three non-identical chains (Ax, Bfl, y) covalently linked by disulphide bonds and joined by symmetrical disulphide bonds between two Aac and two y chains [7] . Three globular domains exist: one central E domain, containing the N-termini of the six chains, and two peripheral D domains, containing the C-terminus [7] . The y chain C-terminal cross-linking site (y 400-411) is indicated in the box. Fragments X, D and E are plasmic products [1] . * denotes new termini generated through initial plasmin cleavage and ** denotes new termini generated through further plasmin cleavage.
Warriner, Chester, Cheshire, U.K.) as oxidizing agent and Na1251 (Amersham International, Amersham, Bucks., U.K.) [14, 15] . The specific radioactivity of the 1251-labelled fibrinogen was [14, 15] , were resuspended at 2 x 107 cells/ml of indicator-free
Hanks balanced salt solution (HBSS). Membranes were prepared by hypotonic lysis of neutrophils and sucrose-density-gradient ultracentrifugation [14, 15] , and cytoskeletons were isolated as a Triton X-100-insoluble fraction [15] . Neutrophil-conditioned medium, devoid of lysosomal enzymes, was prepared by incubating neutrophils (2 x 107/ml) with PMA (5 ng/ml) at 37°C for 20 min [14] . Lysosomal enzymes were obtained by degranulating neutrophils (2 x 107/ml) with N-formyl-L-methionyl-L-leucyl-Lphenylalanine (FMLP; 1 ,sM) in the presence of cytochalasin B (5 ug/ml) [17] . [14, 15] . Gels were dried immediately and the products visualized by autoradiography.
Functional assessment of the fibrinogen degradation products
The thrombin-induced clotting time was determined by adding 5 ,ug of solid ac-antitrypsin and 100 units of aprotinin/ml (5 min, 37°C), followed by 10 #1 of thrombin (bovine plasma, 2 i.u./10 I1), to 100 ,d aliquots of 1251-labelled fibrinogen degradation products generated from 5 min to 20 h by the proteolytic activity of neutrophil-conditioned medium, membranes and cytoskeletons. From a dose-response study using intact 125I-labelled fibrinogen, a 50 % reduction in functional 1251-labelled fibrinogen extended the thrombin-induced clotting time to 35 s. The sample was considered uncoagulateable if clotting had not occurred in 3 min. To detect anticoagulant activity of the degradation products, the clotting time of 100 ,ul of the digest was measured after the addition of 5 ug of solid alantitrypsin and 100 jel of intact '251-labelled fibrinogen (3 mg/ml HBSS), then 1 i.u. of thrombin in 10 4,4.
Production of fibrinogen peptides and separation by h.p.l.c.
Unlabelled fibrinogen (2 mg) was digested with neutrophilconditioned medium and neutrophil membrane and cytoskeleton fractions for various time periods, as described above, in a final volume of 1 ml of HBSS. When required, the degradation reaction was allowed to proceed for 20 h whereupon thrombin (2 i.u./ml) was added to the mixture and the incubation continued for a further 1 h (37°C). Unlabelled fibrinogen (2 mg) was also digested (37°C) for 2 h with 2 ,tg of pure HNE in a final volume of 1 ml of HBSS. All reactions were stopped at the appropriate times by the addition of 50 % (w/v) trichloroacetic acid to a final concentration of 10%. The trichloroacetic acid was extracted from the solubilized peptides with ether before h.p.l.c. analysis [16, 17] . As required, the pH of aliquots of these peptides was adjusted to 7.4, then they were incubated with thrombin (2 i.u./ml) or pure HNE (2 ,ug/ml) for 2 h (37°C). Any remaining high-molecular-mass protein was removed from this digest using a Sep-Pak C18 cartridge (Waters Associates, Milford, MA, U.S.A.), equilibrated with 0.1% trifluoroacetic acid. The adsorbed peptides were eluted with 75% (v/v) acetonitrile in 0.1 % trifluoroacetic acid (3 ml). After evaporation of the solvent the peptides were redissolved in 0.1 % trifluoroacetic acid and subjected to h.p.l.c. analysis. The peptides were separated using a Merck Hibar column (250 cm x 4 mm) prepacked with LiChrosorb RP-18 (5 ,um, E. Merck, Darmstadt, Germany). H.p.l.c. was performed using a Waters Associates liquid chromatograph equipped with a model 600E controller, solvent delivery system (model 6000), automatic injector (model 710B), variable wavelength absorbance detector (model 484 set at 220 nm), and a data module (model M730). The column was loaded with 100,u aliquots of peptide and eluted using a binary gradient formed from 0. 
RESULTS
Identifcation of proteases In conditioned medium from PMAsUmulated neutrophils, neutrophil cytoskeleton and membrane fractions capable of fibrinogenolysis These neutrophil fractions were subjected to SDS/PAGE and gel slices were then incubated with 1251-labelled fibrinogen (1 mg). For each neutrophil fraction approx. 13 %, 40 %, 30 % and 17 % of the total proteolytic activity loaded per track was detectable in gel slices containing molecules which form bands at apparent molecular mass values of 501 kDa, 398 kDa, 316 kDa and 209 kDa respectively. At 24 h these gel slices generated, irrespective of the enzyme source, approx. 180,g, 500 ,ug, 300,g and 230 ,ug of trichloroacetic acid-soluble 1251-labelled fibrinogen peptides/ml, in addition to high-molecular-mass products with apparent molecular mass values identical to those generated by the non-fractionated preparations (see below).
Degradation of fibrinogen by neutrophil-conditloned medium, membranes and cytoskeleton A progressive decrease in the size of intact fibrinogen (340 kDa) and the generation of 1251-labelled fibrinogen derivatives with apparent molecular mass values of less than 340 kDa was observed when 1251-labelled fibrinogen was incubated with conditioned medium (from 5 x 106 PMA-stimulated neutrophils) ( Figure 2) . A similar degradation pattern was observed when the enzyme source was either the neutrophil cytoskeleton or membrane preparation. Each of these neutrophil preparations generated terminal 1251-labelled fibrinogen degradation products which migrated to positions corresponding to apparent molecular mass values of 270 kDA, 200 kDa, 100 kDa and less than 40 kDa ( Figure 3) . No alteration in the apparent molecular mass of these fibrinogen-split products was detected when the CaCl2 in the reaction was chelated with EGTA. These neutrophil-derived 1251_ (Figure 3) . SDS/PAGE analysis, after reduction of the '251-labelled fibrinogen degradation products depicted in Figure 2 , demonstrates cleavage of the constituent chains of fibrinogen (Figure 4 A reduction in the intensity of the radiolabel associated with intact Aa (72 kDa), B,J (58 kDa) and y (48 kDa) chains and the generation of several radiolabelled bands with apparent molecular mass values of less than 48 kDa was observed at 5 min ( Figure 4 ). By 20 min no intact Aa chain (72 kDa) was detected. The increase in intensity of the radiolabel associated with the bands migrating to apparent molecular mass values of 58 kDa (10-30 min, Figure 4 ) and 48 kDa (10 min-9 h, Figure 4) (Figure 4 ). During the degradation process, 125I-labelled fibrinogen trichloroacetic acid-soluble peptides were also generated and were dependent on time of incubation of 125I-labelled fibrinogen with the enzyme and the concentration of the enzyme (Table 1) . No inhibition of fibrinogen degradation by these neutrophil preparations was achieved with e-aminohexanoic acid (200 mM), apro- . tinin (100 units/ml), EDTA (10 mM), leupeptin (100 ,uM, thiol protease inhibitor), phosphoramidon (10,uM, metalloprotease inhibitor), the elastase inhibitors Suc-(Ala)3CH2Cl (1 mM), Suc-(Ala)2-ValCH2Cl (1 mM), or the cathepsin G inhibitor Suc-(Ala)2-Pro-PheCH2Cl (1 mM). Increasing the concentration of these inhibitors did not change the results. When MeO-Suc-(Ala)2-Pro-ValCH2Cl (0.1 mM), which is an inhibitor of proteases with specificities related to alanine or valine bonds, a,-antitrypsin (1.5 mg/ml, elastase inhibitor) or phenylmethanesulphonyl fluoride (PMSF, 1 mM, serine protease inhibitor) were present in the reaction, the production of trichloroacetic acid- Table 2 Amino acid analysis of the peptide with an elution time of 25 min Amino acid sequence: Gly-Glu-Gly-Gln-Gln-His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val.
This corresponds to residues 395-411 from the N-terminus of the y chain. 
Functional assessment of fibrinogen degradation products
Thrombin clotting time increased progressively as 125I-labelled fibrinogen was degraded by the proteolytic activity of neutrophilconditioned medium, cytoskeletons and membranes. The product with an apparent molecular mass of 330 kDa (30 min, Figure 1 ), increased the thrombin clotting time beyond 25 s, while the product with an apparent molecular mass of 310 kDa (1.5 h, Figure 1 ) caused the clotting time to be greater than 3 min. No clot formed when the 1251-labelled fibrinogen product with an apparent molecular mass of 290 kDa (3 h, Figure 1 ) was treated with thrombin. None of the 125I-labelled fibrinogen degradation products generated by either neutrophil-conditioned medium, isolated cytoskeletons or membranes exhibited anticoagulant activity.
H.p.l.c. analysis of the trichloroacetic acid-soluble fibrinogen degradation products
The trichloroacetic acid-soluble fibrinogen peptides were separated by h.p.l.c. to identify N-terminal Aa and B/) and Cterminal y chain-released peptides ( Figure 5 ). C-terminal y chain peptides were sought as the products lack anticoagulant activity. Peptides which were eluted between 23 and 27 min were identified on the basis of the elution time of synthetic peptides corresponding to the amino acid sequence at positions 397-411, 400-411, and 402-411 from the N-terminus of the y chain. A peptide which was eluted at 25 min was found to have an amino acid composition corresponding to the amino acid sequence at positions 396-411 from the N-terminus of the y chain (Table 2 ) (Figure 5a ). This peptide was observed at 5 min and the size of this peak increased and reached a maximum at 3 h.
Co-injection of synthetic fibrinopeptide A (Aal-16 peptide) and B (B,/1-14 peptide) with the trichloroacetic acid-soluble fibrinogen peptides revealed the absence of peptides with retention times the same as these synthetic peptides in the mixture (Figure 5a ). The presence of fibrinopeptide A-and fibrinopeptide B-containing fragments was determined by treating the peptide mixture with thrombin ( Figure 5a ). This cleaved three peptides with retention times of 37.6, 38.3 and 38.8 min and generated a peptide with a retention time equivalent to that of synthetic fibrinopeptide A (Figure 5b ). No peptide with a retention time equivalent to that of synthetic fibrinopeptide B was generated Table 3 Amino acid analysis of the peptide having an eluton time of 38.3 min Amino acid sequence: Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg-GlyPro-Arg-Val-Val. This corresponds to residues 1-21 from the N-terminus of the Act chain. [4] , further experiments were conducted to confirm that this peptide could also be generated by a neutral neutrophil protease, seemingly unrelated to granule elastase: (i) the peptides formed by this protease were tested for the presence of elastase-sensitive sites; (ii) the ability of neutrophil-conditioned medium to generate the Aal-21 peptide in the presence of neutrophil elastase inhibitor, MeO-Suc-(Ala)2-Pro-ValCH2Cl, was examined; and (iii) the h.p.l.c. profile of fibrinogen peptides generated by neutrophil-conditioned medium and HNE were compared. Although several peptides generated by neutrophil-conditioned medium ( Figure Sa (Table 3 ). The yield of Aal-21 (as judged by peak heights and area under the peak) was more than 98 % of that in the absence of this inhibitor. In contrast with the inability of MeO-Suc-(Ala)2-Pro-ValCH2Cl to inhibit Aal-21 formation by neutrophil-conditioned media, the inhibitor completely prevented fibrinogen digestion by HNE (Figure 5f ). Finally, HNE digestion of fibrinogen produced many peptides with retention times different from those produced by conditioned medium from PMA-stimulated neutrophils (Figure 5g ). When the HNE-generated peptides were treated with thrombin, a peptide with a retention time of 38.3 min was cleaved and a peptide which was eluted with a retention time equivalent to that of pure fibinopeptide A was detected ( Figure   5h ). This peptide, when isolated, co-eluted with the peptide having a retention time of 38.3 min which was generated by conditioned medium degradation of fibrinogen pre- (Figure 5a ) and post- (Figure 5d ) HNE treatment.
Similar peptide profiles, with characteristics as described for those generated by neutrophil-conditioned medium, were obtained when the enzyme source was either neutrophil cytoskeleton or membrane preparations (results not shown).
DISCUSSION
This study demonstrates the capacity of a neutral protease, associated with isolated neutrophil membranes, cytoskeletons and the conditioned medium obtained from PMA-stimulated neutrophils, to cleave fibrinogen, in a manner dependent on time and concentration, to a non-clottable form. The protease within each of these neutrophil fractions, responsible for fibrinogenolysis, was found to migrate on SDS/PAGE as four discrete bands having molecular mass values of 209, 316, 398 and 501 kDa. Each of these neutrophil fractions has previously been reported to contain a neutral enzyme complex with an apparent molecular mass of 600 kDa which can be dissociated with SDS to four discrete bands with these same apparent molecular mass values [15] . The fibrinogenolysis by each of these neutrophil fractions generated fibrinogen degradation products with distinctly different molecular mass values from those produced by plasmin, neutrophil lysosomal enzymes and pure HNE, and was resistant to inhibition by the chloromethyl ketone inhibitor MeO-Suc-(Ala)2-Pro-ValCH2Cl, unlike the proteolytic activity of HNE which appears to be sensitive to this inhibitor [4, [11] [12] [13] . Other specific inhibitors of HNE and also plasmin inhibitors had no effect on fibrinogenolysis by this neutrophil-membraneassociated protease.
In the presence or absence ofCaCl2 simultaneous early cleavage ofall three constituent chains offibrinogen to produce unclottable fibrinogen products, which do not exhibit anticoagulant activity, appears to be a characteristic of the fibrinogenolytic process by this membrane-associated protease. Release of an Aal-21 peptide, fibrinopeptide B, from the high-molecular-mass split products and a 17-amino-acid C-terminus a-chain peptide indicates fibrinogenolysis occur in the N-terminal region of the Aa chain and the C-terminal regions of the B,8 and y chains. Such proteolysis of the Aa and y chains could account for the products lacking anticoagulant activity [8, 9] .
In contrast with fibrinogenolysis by this neutrophil-membraneassociated protease, neutrophil lysates and purified HNE cleave all three chains of fibrinogen from the N-terminus [2, 3, 5, 10] , and plasmin attacks the C-terminus of the Ao chain and the Nterminus of the B/I chain, with the y chain being plasmin resistant, particularly in the presence of CaCl2 [1] . In addition, the fibrinogenolytic pathways used by plasmin and neutrophil lysates have been reported to produce anticoagulants [1] [2] [3] 5, 10] .
Several studies have concluded that HNE is responsible for the formation of an Aal-21 peptide found in the serum of normal individuals and patients with -a1-antitrypsin deficiency [4, 12, 13] . We confirm the ability of pure HNE to generate the thrombinsensitive fibrinopeptide A-containing peptide and demonstrate that an identical peptide can be generated by the proteolytic activity of the neutrophil membrane. The formation of this peptide by the neutrophil-membrane-associated protease was insensitive to inhibition by MeO-Suc-(Ala)2-Pro-ValCH2Cl that has been shown in several studies, and now been confirmed by us, to completely inhibit HNE formation of this peptide [4, [11] [12] [13] . When non-stimulated neutrophils were incubated with fibrinogen-coated filters an HNE-insensitive pathway for forming the Aal-21 peptide was described [12] . This could be due to the action of the membrane protease as it does exhibit activity in non-stimulated neutrophils [14] . Only the bond between amino acids 21 and 22 seems to be sensitive to both elastase and the proteolytic activity of the neutrophil membrane. Other elastasespecific sites in fibrinogen appear to be markedly different from those susceptible to cleavage by the neutrophil-membraneassociated protease.
The exact structure and catalytic propertids of the neutrophilmembrane-associated neutral protease, described in this study to possess fibrinogenolytic activity, has not been elucidated. Neutrophil granules contain several closely related neutral proteases: elastase, cathepsin G and proteinase 3 [18] . These proteases have considerable amino-acid-sequence similarity and possess elastase-like activity. However, their specific catalytic properties, and the fact that each is sensitive to a specific spectrum of inhibitors [18] , indicates each to be a distinct neutrophil granule proteinase. The neutrophil-membrane-associated neutral protease could be a member of the family of elastase-like enzymes of the neutrophil. The fact that this enzyme exists as a highmolecular-mass complex may account for it behaving differently from elastase with respect to cleavage specificity and sensitivity to inhibition by elastase inhibitors.
From the results presented in this study it may be postulated that fibrinogenolysis by a protease within the neutrophil membrane could be important for the regulation of fibrin deposition. This proteolytic activity may consequently play a major role at sites of inflammation where neutrophils and fibrinogen are in close contaet. In addition, the possibility exists that this enzyme could be reflected in vivo in the level of the Aal-21 peptide found in plasma. Received 18 December 1992/9 September 1993; accepted 28 September 1993
